Praxis Precision Medicines (NASDAQ:PRAX) Issues Earnings Results

Key Points

• NDAs accepted for ulixacaltamide and relutrigine with PDUFA dates set for Jan 29 and Sep 27, and the company is scaling its commercial, distribution and payer/access efforts ahead of potential U.S. launches.
• Key clinical catalysts: EMERALD enrollment is complete with top-line results due in Q4 that could support a supplemental NDA to expand relutrigine, and EMBRAVE Part A showed the ASO elsunersen produced a 77% placebo‑adjusted reduction in monthly seizures in SCN2A early‑onset DEE.
• Praxis reported a ($3.20) EPS loss that beat consensus ($3.58) and endures a strengthened cash position of about $1.4B after a January follow‑on, which management says funds operations into 2028.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($3.20) EPS for the quarter, beating analysts' consensus estimates of ($3.58) by $0.38, FiscalAI reports.

Here are the key takeaways from Praxis Precision Medicines' conference call:

• NDAs accepted for ulixacaltamide and relutrigine with PDUFA dates set (ulixacaltamide: Jan 29; relutrigine: Sep 27), and the company is scaling its commercial organization, distribution and payer/access efforts ahead of potential U.S. launches.
• Enrollment for the EMERALD study is complete and top-line results are expected in Q4; a positive readout could support a supplemental NDA to expand relutrigine into the broader DEE population (~200,000 U.S. patients), materially increasing commercial potential.
• EMBRAVE Part A data for the Solidus ASO elsunersen showed a 77% placebo‑adjusted reduction in monthly seizures and signs of disease‑modifying benefit in SCN2A early‑onset DEE with a generally favorable tolerability profile.
• The vormatrigine program has near‑term catalysts — POWER1 readout later this quarter and ongoing POWER2/POWER3 studies — and management reports encouraging blinded safety data and expectation of meaningful efficacy across flexible 20/30/40 mg dosing.
• Q1 financials showed operating expenses of ~$106M and $86M of cash used (up versus prior year) but a strengthened cash balance of ~$1.4B after a January follow‑on offering, which management says funds operations into 2028.

Praxis Precision Medicines Stock Down 1.4%

PRAX stock traded down $4.79 during trading on Thursday, hitting $333.28. The company had a trading volume of 457,694 shares, compared to its average volume of 461,717. The firm has a 50-day moving average price of $317.97 and a 200-day moving average price of $276.55. Praxis Precision Medicines has a 12 month low of $35.21 and a 12 month high of $356.00. The stock has a market cap of $9.29 billion, a price-to-earnings ratio of -24.76 and a beta of 2.76.

Analysts Set New Price Targets

A number of research firms have commented on PRAX. BTIG Research restated a "buy" rating and issued a $843.00 price target on shares of Praxis Precision Medicines in a research report on Monday, April 6th. Truist Financial upgraded shares of Praxis Precision Medicines to a "strong-buy" rating in a research report on Wednesday, March 25th. Guggenheim restated a "buy" rating and issued a $800.00 price target (up from $760.00) on shares of Praxis Precision Medicines in a research report on Tuesday, February 10th. Wedbush boosted their price target on shares of Praxis Precision Medicines from $95.00 to $130.00 and gave the company an "underperform" rating in a research report on Friday, February 20th. Finally, Wells Fargo & Company set a $305.00 price target on shares of Praxis Precision Medicines and gave the company an "equal weight" rating in a research report on Friday, February 20th. Five research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $590.78.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. bought a new position in Praxis Precision Medicines in the 4th quarter worth approximately $81,464,000. Invesco Ltd. lifted its holdings in Praxis Precision Medicines by 269.4% in the fourth quarter. Invesco Ltd. now owns 77,088 shares of the company's stock valued at $22,721,000 after buying an additional 56,220 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in Praxis Precision Medicines in the fourth quarter valued at approximately $357,000. Mackenzie Financial Corp acquired a new position in Praxis Precision Medicines in the fourth quarter valued at approximately $415,000. Finally, Coastal Bridge Advisors LLC lifted its holdings in Praxis Precision Medicines by 8.0% in the fourth quarter. Coastal Bridge Advisors LLC now owns 4,154 shares of the company's stock valued at $1,224,000 after buying an additional 308 shares during the period. Institutional investors own 67.84% of the company's stock.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company's pipeline includes several lead candidates at various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.